ASTRAZENECA PHARMA | GUJ.THEMIS. | ASTRAZENECA PHARMA/ GUJ.THEMIS. |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 198.7 | 68.3 | 291.1% | View Chart |
P/BV | x | 23.0 | 17.9 | 128.6% | View Chart |
Dividend Yield | % | 0.4 | 0.3 | 121.7% |
ASTRAZENECA PHARMA GUJ.THEMIS. |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASTRAZENECA PHARMA Mar-24 |
GUJ.THEMIS. Mar-24 |
ASTRAZENECA PHARMA/ GUJ.THEMIS. |
5-Yr Chart Click to enlarge
|
||
High | Rs | 7,208 | 1,069 | 674.3% | |
Low | Rs | 3,102 | 162 | 1,911.3% | |
Sales per share (Unadj.) | Rs | 518.2 | 23.4 | 2,216.6% | |
Earnings per share (Unadj.) | Rs | 64.6 | 8.1 | 793.2% | |
Cash flow per share (Unadj.) | Rs | 70.6 | 8.6 | 817.7% | |
Dividends per share (Unadj.) | Rs | 24.00 | 1.00 | 2,400.0% | |
Avg Dividend yield | % | 0.5 | 0.2 | 286.6% | |
Book value per share (Unadj.) | Rs | 283.5 | 27.7 | 1,022.5% | |
Shares outstanding (eoy) | m | 25.00 | 72.64 | 34.4% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 9.9 | 26.3 | 37.8% | |
Avg P/E ratio | x | 79.8 | 75.6 | 105.6% | |
P/CF ratio (eoy) | x | 73.0 | 71.3 | 102.4% | |
Price / Book Value ratio | x | 18.2 | 22.2 | 81.9% | |
Dividend payout | % | 37.1 | 12.3 | 302.6% | |
Avg Mkt Cap | Rs m | 128,875 | 44,723 | 288.2% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 2,415 | 102 | 2,363.7% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 12,955 | 1,698 | 762.9% | |
Other income | Rs m | 348 | 44 | 797.1% | |
Total revenues | Rs m | 13,303 | 1,742 | 763.7% | |
Gross profit | Rs m | 2,009 | 787 | 255.1% | |
Depreciation | Rs m | 149 | 35 | 422.5% | |
Interest | Rs m | 12 | 2 | 524.0% | |
Profit before tax | Rs m | 2,195 | 793 | 276.7% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 580 | 202 | 287.7% | |
Profit after tax | Rs m | 1,615 | 592 | 273.0% | |
Gross profit margin | % | 15.5 | 46.4 | 33.4% | |
Effective tax rate | % | 26.4 | 25.4 | 104.0% | |
Net profit margin | % | 12.5 | 34.8 | 35.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 10,427 | 676 | 1,542.5% | |
Current liabilities | Rs m | 4,672 | 362 | 1,290.6% | |
Net working cap to sales | % | 44.4 | 18.5 | 240.3% | |
Current ratio | x | 2.2 | 1.9 | 119.5% | |
Inventory Days | Days | 47 | 95 | 49.5% | |
Debtors Days | Days | 43 | 581 | 7.4% | |
Net fixed assets | Rs m | 2,342 | 1,736 | 134.9% | |
Share capital | Rs m | 50 | 73 | 68.8% | |
"Free" reserves | Rs m | 7,036 | 1,941 | 362.5% | |
Net worth | Rs m | 7,086 | 2,014 | 351.9% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 12,769 | 2,412 | 529.5% | |
Interest coverage | x | 184.0 | 347.4 | 52.9% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 1.0 | 0.7 | 144.1% | |
Return on assets | % | 12.7 | 24.6 | 51.7% | |
Return on equity | % | 22.8 | 29.4 | 77.6% | |
Return on capital | % | 31.2 | 39.5 | 78.8% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0.5 | 1.9 | 24.6% | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 61 | 33 | 187.7% | |
Fx inflow | Rs m | 1,094 | 0 | - | |
Fx outflow | Rs m | 61 | 33 | 187.7% | |
Net fx | Rs m | 1,033 | -33 | -3,178.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 279 | 642 | 43.4% | |
From Investments | Rs m | 217 | -552 | -39.4% | |
From Financial Activity | Rs m | -444 | -86 | 516.8% | |
Net Cashflow | Rs m | 52 | 4 | 1,263.3% |
Indian Promoters | % | 0.0 | 70.9 | - | |
Foreign collaborators | % | 75.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 8.0 | 2.7 | 300.8% | |
FIIs | % | 2.9 | 1.5 | 194.6% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 25.0 | 29.1 | 85.8% | |
Shareholders | 27,615 | 31,271 | 88.3% | ||
Pledged promoter(s) holding | % | 0.0 | 3.3 | - |
Compare ASTRAZENECA PHARMA With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB MANKIND PHARMA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | ASTRAZENECA PHARMA | GUJ.THEMIS. | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | 0.21% | 1.54% | -0.51% |
1-Month | -7.73% | 16.09% | -1.45% |
1-Year | 37.07% | 168.14% | 44.29% |
3-Year CAGR | 25.95% | 0.03% | 18.87% |
5-Year CAGR | 19.52% | 60.00% | 25.62% |
* Compound Annual Growth Rate
Here are more details on the ASTRAZENECA PHARMA share price and the GUJ.THEMIS. share price.
Moving on to shareholding structures...
The promoters of ASTRAZENECA PHARMA hold a 75.0% stake in the company. In case of GUJ.THEMIS. the stake stands at 70.9%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of ASTRAZENECA PHARMA and the shareholding pattern of GUJ.THEMIS..
Finally, a word on dividends...
In the most recent financial year, ASTRAZENECA PHARMA paid a dividend of Rs 24.0 per share. This amounted to a Dividend Payout ratio of 37.1%.
GUJ.THEMIS. paid Rs 1.0, and its dividend payout ratio stood at 12.3%.
You may visit here to review the dividend history of ASTRAZENECA PHARMA, and the dividend history of GUJ.THEMIS..
For a sector overview, read our pharmaceuticals sector report.
After starting the day on a flattish note with a positive bias, the benchmarks showcased heightened volatility and ended the day weak.